Compare Sanofi SA (SNY) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vistra Corp — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Vistra Corp trades at $162.3 (market cap $53.27B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | VST | |
|---|---|---|
Market Cap | $104.83B | $53.27B |
Sector | Health | Technology |
52-Week High | $52.34 | $217.92 |
52-Week Low | $41.33 | $134.71 |
Enterprise Value | $121.32B | $75.03B |
Dividend Yield | 5.5% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vistra Corp (VST) trades at $157.99, up 1.64% today, showing mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported strong Q1 2026 earnings beat ($2.87 vs $1.32 expected) after previous misses, with 2026 revenue projected at $19.4B and net profit margin improving to 11.52%. Recent news highlights Vistra's positioning as a potential beneficiary of AI-driven power demand growth.
Wall Street maintains strong bullish sentiment with 91% buy ratings and a $253 consensus price target representing 60% upside potential. Key risks include power price volatility, high debt levels, and project execution challenges. The company's long-term power purchase agreements with major tech firms provide revenue visibility, but investors should monitor Q2 2026 earnings due August 7th for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
